WO1993005021A1 - 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof - Google Patents

4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof Download PDF

Info

Publication number
WO1993005021A1
WO1993005021A1 PCT/JP1992/001139 JP9201139W WO9305021A1 WO 1993005021 A1 WO1993005021 A1 WO 1993005021A1 JP 9201139 W JP9201139 W JP 9201139W WO 9305021 A1 WO9305021 A1 WO 9305021A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclohexane
amino
alkyl
coronary
cerebral
Prior art date
Application number
PCT/JP1992/001139
Other languages
English (en)
French (fr)
Inventor
Masafumi Arita
Tadamasa Saito
Hirofumi Okuda
Hiroyuki Sato
Masayoshi Uehata
Original Assignee
Yoshitomi Pharmaceutical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical Industries, Ltd. filed Critical Yoshitomi Pharmaceutical Industries, Ltd.
Priority to KR1019940700738A priority Critical patent/KR0133372B1/ko
Priority to DK92918882T priority patent/DK0641781T3/da
Priority to KR1019940700738A priority patent/KR940702451A/ko
Priority to DE69231297T priority patent/DE69231297T2/de
Priority to AT92918882T priority patent/ATE194977T1/de
Priority to EP92918882A priority patent/EP0641781B1/en
Priority to US08/204,211 priority patent/US5478838A/en
Publication of WO1993005021A1 publication Critical patent/WO1993005021A1/ja
Priority to GR20000402319T priority patent/GR3034633T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
PCT/JP1992/001139 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof WO1993005021A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1019940700738A KR0133372B1 (ko) 1991-09-06 1992-09-04 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
DK92918882T DK0641781T3 (da) 1991-09-06 1992-09-04 4-Amino(alkyl)cyclohexan-1-carboxamidforbindelser og anvendelse af disse
KR1019940700738A KR940702451A (ko) 1991-09-06 1992-09-04 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
DE69231297T DE69231297T2 (de) 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexan-1-carboxamidverbindungen und ihre verwendung
AT92918882T ATE194977T1 (de) 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexan-1-carboxamidverbindung n und ihre verwendung
EP92918882A EP0641781B1 (en) 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
US08/204,211 US5478838A (en) 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
GR20000402319T GR3034633T3 (en) 1991-09-06 2000-10-16 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP25568991 1991-09-06
JP3/255689 1991-09-06
JP14617592 1992-05-12
JP4/146175 1992-05-12

Publications (1)

Publication Number Publication Date
WO1993005021A1 true WO1993005021A1 (en) 1993-03-18

Family

ID=26477067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1992/001139 WO1993005021A1 (en) 1991-09-06 1992-09-04 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof

Country Status (10)

Country Link
US (1) US5478838A (ja)
EP (1) EP0641781B1 (ja)
KR (2) KR940702451A (ja)
AT (1) ATE194977T1 (ja)
CA (1) CA2117096C (ja)
DE (1) DE69231297T2 (ja)
DK (1) DK0641781T3 (ja)
ES (1) ES2148179T3 (ja)
GR (1) GR3034633T3 (ja)
WO (1) WO1993005021A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757038A1 (en) * 1994-04-18 1997-02-05 Yoshitomi Pharmaceutical Industries, Ltd. Benzamide compound and medicinal use thereof
WO2001056988A1 (fr) 2000-02-01 2001-08-09 Kirin Beer Kabushiki Kaisha Composes contenant de l'azote et possedant une activite d'inhibition des kinases, et medicaments comprenant ces composes
JP2008525463A (ja) * 2004-12-22 2008-07-17 インサイト・コーポレイション ＪＡＮＵＳキナーゼ阻害剤としてのピロロ［２，３−ｂ］ピリジン−４−イル−アミンおよびピロロ［２，３−ｂ］ピリミジン−４−イル−アミン
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2014014050A1 (ja) 2012-07-19 2014-01-23 大日本住友製薬株式会社 １－（シクロアルキルカルボニル）プロリン誘導体

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2169719C (en) * 1994-06-21 2002-04-16 Yasuo Shoji Pyrazolo[1,5-a]pyrimidine derivative
DK0956865T4 (da) 1996-08-12 2010-11-22 Mitsubishi Tanabe Pharma Corp Medikamenter omfattende Rho-kinaseinhibitor
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
EP1459743B9 (en) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US6720341B2 (en) 2000-03-31 2004-04-13 Mitsubishi Pharma Corporation Preventives/remedies for kidney diseases
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
JP4204326B2 (ja) * 2001-04-11 2009-01-07 千寿製薬株式会社 視覚機能障害改善剤
MXPA04010441A (es) * 2002-04-23 2005-02-14 Shionogi & Co Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo.
US20040028716A1 (en) * 2002-06-14 2004-02-12 Marks Andrew R. Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
CA2400996A1 (en) * 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2007502772A (ja) 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド ４−シクロアルキルアミノピラゾロピリミジンｎｍｄａ／ｎｒ２ｂ拮抗薬
GB0403635D0 (en) * 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
JP2007523202A (ja) * 2004-02-24 2007-08-16 ビオアクソン・テラプティーク・インコーポレーテッド ４置換ピペリジン誘導体
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
KR20090106604A (ko) * 2007-01-12 2009-10-09 아스텔라스세이야쿠 가부시키가이샤 축합 피리딘 화합물
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) * 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
AU2010315712B2 (en) 2009-10-19 2014-04-17 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte production
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2012087965A2 (en) 2010-12-22 2012-06-28 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
JP2014520551A (ja) 2011-07-11 2014-08-25 セルラー ダイナミクス インターナショナル， インコーポレイテッド 細胞のリプログラミング方法およびゲノムの改変方法
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10266807B2 (en) 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
EP3114214B1 (en) 2014-03-04 2023-11-01 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
US10149856B2 (en) 2015-01-26 2018-12-11 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
WO2017075389A1 (en) 2015-10-30 2017-05-04 The Regents Of The Universtiy Of California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
US20230117572A1 (en) * 2019-12-30 2023-04-20 Memorial Sloan Kettering Cancer Center Small molecule inhibitors of ulk1
EP4142879A1 (en) 2020-04-27 2023-03-08 Novartis AG Methods and compositions for ocular cell therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456661A (en) * 1987-05-29 1989-03-03 Yoshitomi Pharmaceutical Amino pyridine derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (en) * 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Trans-4-amino(alkyl)-1-pyridylcarbamoyl-cyclohexane compounds and their medicinal use
JP2770497B2 (ja) * 1988-11-24 1998-07-02 吉富製薬株式会社 トランス―４―アミノ（アルキル）―１―ピリジルカルバモイルシクロヘキサン化合物およびその医薬用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456661A (en) * 1987-05-29 1989-03-03 Yoshitomi Pharmaceutical Amino pyridine derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 113, No. 19, 171894a (1990). *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0757038A1 (en) * 1994-04-18 1997-02-05 Yoshitomi Pharmaceutical Industries, Ltd. Benzamide compound and medicinal use thereof
EP0757038A4 (en) * 1994-04-18 1997-08-06 Yoshitomi Pharmaceutical BENZAMIDE COMPOUND AND THEIR MEDICAL USE
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
EP1391454A1 (en) 1994-04-18 2004-02-25 Mitsubishi Pharma Corporation Substituted benzamide compounds with antihypertensive activity
WO2001056988A1 (fr) 2000-02-01 2001-08-09 Kirin Beer Kabushiki Kaisha Composes contenant de l'azote et possedant une activite d'inhibition des kinases, et medicaments comprenant ces composes
JP2008525463A (ja) * 2004-12-22 2008-07-17 インサイト・コーポレイション ＪＡＮＵＳキナーゼ阻害剤としてのピロロ［２，３−ｂ］ピリジン−４−イル−アミンおよびピロロ［２，３−ｂ］ピリミジン−４−イル−アミン
JP2012140469A (ja) * 2004-12-22 2012-07-26 Incyte Corp ＪＡＮＵＳキナーゼ阻害剤としてのピロロ［２，３−ｂ］ピリジン−４−イル−アミンおよびピロロ［２，３−ｂ］ピリミジン−４−イル−アミン
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2014014050A1 (ja) 2012-07-19 2014-01-23 大日本住友製薬株式会社 １－（シクロアルキルカルボニル）プロリン誘導体

Also Published As

Publication number Publication date
ATE194977T1 (de) 2000-08-15
ES2148179T3 (es) 2000-10-16
DE69231297D1 (de) 2000-08-31
EP0641781A1 (en) 1995-03-08
US5478838A (en) 1995-12-26
EP0641781B1 (en) 2000-07-26
KR940702451A (ko) 1994-08-20
CA2117096A1 (en) 1993-03-18
DK0641781T3 (da) 2000-09-18
GR3034633T3 (en) 2001-01-31
CA2117096C (en) 1997-11-04
DE69231297T2 (de) 2000-11-23
KR0133372B1 (ko) 1998-04-23
EP0641781A4 (en) 1994-12-16

Similar Documents

Publication Publication Date Title
WO1993005021A1 (en) 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
EP0664289A3 (en) Isoquinolines
CA2250586A1 (en) Meta-substituted phenylene sulphonamide derivatives
CA2287558A1 (en) Heterocyclic derivatives and their use as antithrombotic agents
CA2210022A1 (en) Paroxetine hydrochloride solvates
EP1213285A3 (en) 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors
EP0393493A3 (en) Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
CA2119783A1 (en) Substituted phenserines and phenylcarbamates of (-)-eseroline, (-)-n1-noreseroline, and (-)-n1-benzylnoreseroline; as specific inhibitors of acetylcholinesterase
EP0392802A3 (en) Preparation of urea analogues and their use in bronchial, cerebrovascular and neuronal disorders
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
NZ508585A (en) Metabolites of ecteinascidin 743
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
AU6471200A (en) Substituted aromatic-ring compounds, process for producing the same, and use
CA2150546A1 (en) Agent for inhibiting production of interleukin-8
DK0712398T3 (da) Benzopyraner og farmaceutiske præparater, der indeholder dem
WO1996005836A3 (en) Methods of treating cold symptoms using pentoxifylline
CA2118425A1 (en) Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof
AU655869B2 (en) An amphoteric tricyclic compound
WO1998003540A3 (en) 1,2-substituted cycloalkane derivatives as thrombine inhibitors, a process for the preparation thereof and the use thereof in pharmaceutical formulations
EP0302633A3 (en) Beta-lactam compound, process for preparing the same, intermediate for synthesis of the same and medicinal composition for bacterially infectious disease therapy containing the same
FI950925A (fi) Fosfono-substituoidut tetratsolijohdannaiset
EP0401049A3 (en) Beta-lactam elastase inhibitors
CA2239053A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
PT777471E (pt) Metodo de inibicao da biosintese de leucotrieno

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA HU KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2117096

Country of ref document: CA

Ref document number: 1992918882

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019940700738

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 08204211

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1992918882

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992918882

Country of ref document: EP